As of 2024-12-14, the EV/EBITDA ratio of Sorrento Therapeutics Inc (SRNE) is -0.21. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SRNE's latest enterprise value is 73.06 mil USD. SRNE's TTM EBITDA according to its financial statements is -340.66 mil USD. Dividing these 2 quantities gives us the above SRNE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 15.1x - 18.6x | 16.6x |
| Forward P/E multiples | 15.3x - 26.1x | 20.2x |
| Fair Price | (2,454.78) - (2,970.66) | (2,949.29) |
| Upside | -798921.2% - -966795.7% | -959843.8% |
| Date | EV/EBITDA |
| 2024-11-29 | -0.21 |
| 2024-11-27 | -0.21 |
| 2024-11-26 | -0.21 |
| 2024-11-25 | -0.21 |
| 2024-11-22 | -0.21 |
| 2024-11-21 | -0.21 |
| 2024-11-20 | -0.21 |
| 2024-11-19 | -0.21 |
| 2024-11-18 | -0.21 |
| 2024-11-15 | -0.21 |
| 2024-11-14 | -0.21 |
| 2024-11-13 | -0.21 |
| 2024-11-12 | -0.21 |
| 2024-11-11 | -0.21 |
| 2024-11-08 | -0.21 |
| 2024-11-07 | -0.21 |
| 2024-11-06 | -0.21 |
| 2024-11-05 | -0.21 |
| 2024-11-04 | -0.21 |
| 2024-11-01 | -0.21 |
| 2024-10-31 | -0.21 |
| 2024-10-30 | -0.21 |
| 2024-10-29 | -0.21 |
| 2024-10-28 | -0.21 |
| 2024-10-25 | -0.21 |
| 2024-10-24 | -0.21 |
| 2024-10-23 | -0.21 |
| 2024-10-22 | -0.21 |
| 2024-10-21 | -0.21 |
| 2024-10-18 | -0.21 |
| 2024-10-17 | -0.21 |
| 2024-10-16 | -0.21 |
| 2024-10-15 | -0.21 |
| 2024-10-14 | -0.21 |
| 2024-10-11 | -0.21 |
| 2024-10-10 | -0.21 |
| 2024-10-09 | -0.21 |
| 2024-10-08 | -0.21 |
| 2024-10-07 | -0.21 |
| 2024-10-04 | -0.21 |
| 2024-10-03 | -0.21 |
| 2024-10-02 | -0.21 |
| 2024-10-01 | -0.21 |
| 2024-09-30 | -0.21 |
| 2024-09-27 | -0.21 |
| 2024-09-26 | -0.21 |
| 2024-09-25 | -0.21 |
| 2024-09-24 | -0.21 |
| 2024-09-23 | -0.21 |
| 2024-09-20 | -0.21 |